Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study
Frontiers in Cellular and Infection Microbiology · 20.05.2026 · 16
DOI: 10.3389/fcimb.2026.1824625 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 20.05.2026. Verfasst von Jianpan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Colistin, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Carbapenems. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Municipal Health and Family Planning Commission.
Abstract (Originalsprache)
Objective
To evaluate the clinical outcomes of colistimethate sodium (CMS) in Chinese patients with carbapenem-resistant Gram-negative bacterial (CR-GNB) infections and to identify predictors associated with clinical outcomes.
Methods
A retrospective cohort study was performed in patients with CR-GNB infections who received CMS treatment between April 2022 and December 2025. The primary outcome was clinical efficacy; secondary outcomes included bacterial eradication and all-cause mortality. Predictors were identified using multivariable logistic and Cox regression.
Results
A total of 169 patients were included. The clinical efficacy was 40.8%, microbiological eradication was 50.3%, and all-cause mortality was 36.7%. Multivariate analysis showed that colistin MIC ≤ 0.5 mg/L (adjusted odds ratio [aOR] 3.495; 95% confidence interval [CI] 1.279–9.554; p = 0.015) and duration of CMS therapy (aOR 1.143; 95% CI 1.062–1.229; p < 0.001) were independently associated with favorable clinical efficacy, whereas vasoactive agent use (aOR 0.183; 95% CI 0.062–0.538; p = 0.002) and CMS monotherapy (aOR 0.076; 95% CI 0.008–0.706; p = 0.024) were inversely correlated with clinical success. Patients treated for 14–21 days with a cumulative CMS dose of 40–50 mg CBA/kg tended to have more favorable clinical outcomes. Combination with nebulization (adjusted hazard ratio [aHR] 0.416; 95% CI 0.246–0.703; p = 0.001) and concomitant β−lactam/β−lactamase inhibitor combinations (aHR 0.556; 95% CI 0.316–0.978; p = 0.042) were associated with lower all-cause mortality.
Conclusion
CMS demonstrated potential therapeutic value in the treatment of CR-GNB infections. Longer treatment durations (particularly 14–21 days) and combination therapy were independent predictors of higher clinical efficacy. Adjunctive nebulized CMS therapy correlated with reduced all-cause mortality, particularly in patients with respiratory tract infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Förderung
- Guangzhou Municipal Health and Family Planning Commission
Zitieren
APA
Zhang, J., Peng, H., Liao, J., Wang, R., Wu, X., & Chen, L. (2026). Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1824625
Vancouver
Zhang J, Peng H, Liao J, Wang R, Wu X, Chen L. Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1824625
BibTeX
@article{Zhang2026,
author = {Zhang, Jianpan and Peng, Huaidong and Liao, Jiajia and Wang, Ruolun and Wu, Xiaoli and Chen, Lijin},
title = {Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1824625}
}
EUVIMED